Lumithera CEO Discusses FDA Authorization for Veleda for Dry AMD episode artwork

EPISODE · Nov 20, 2024 · 10 MIN

Lumithera CEO Discusses FDA Authorization for Veleda for Dry AMD

from Eyewire News: The Podcast · host Eyewire News

The CEO of Lumithera joins us to discuss the FDA authorization of the Veleda system for dry AMD; the FDA accepts the resubmitted NDA for dry eye disease candidate reproxalap; and Alcon launches the first contact lens designed for a 1-week replacement cycle. Learn more about your ad choices. Visit megaphone.fm/adchoices

NOW PLAYING

Lumithera CEO Discusses FDA Authorization for Veleda for Dry AMD

0:00 10:46

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Frequently Asked Questions

How long is this episode of Eyewire News: The Podcast?

This episode is 10 minutes long.

When was this Eyewire News: The Podcast episode published?

This episode was published on November 20, 2024.

What is this episode about?

The CEO of Lumithera joins us to discuss the FDA authorization of the Veleda system for dry AMD; the FDA accepts the resubmitted NDA for dry eye disease candidate reproxalap; and Alcon launches the first contact lens designed for a 1-week...

Can I download this Eyewire News: The Podcast episode?

Yes, you can download this episode by clicking the download button on the episode player, or subscribe to the podcast in your preferred podcast app for automatic downloads.
URL copied to clipboard!